{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glutamine&page=2",
    "query": {
      "intervention": "glutamine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glutamine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T06:32:47.257Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04471415",
      "title": "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "DRP-104",
          "type": "DRUG"
        },
        {
          "name": "atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Dracen Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2020-08-31",
      "completion_date": "2023-03-28",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04471415"
    },
    {
      "nct_id": "NCT03163667",
      "title": "CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2017-09-06",
      "completion_date": "2020-06-01",
      "has_results": true,
      "last_update_posted_date": "2022-09-15",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03163667"
    },
    {
      "nct_id": "NCT00005775",
      "title": "Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature",
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "Glutamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "72 Hours",
        "sex": "ALL",
        "summary": "Up to 72 Hours"
      },
      "enrollment_count": 1433,
      "start_date": "1999-07",
      "completion_date": "2001-08",
      "has_results": false,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005775"
    },
    {
      "nct_id": "NCT03113617",
      "title": "68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Prostate Adenocarcinoma",
        "Stage III Prostate Adenocarcinoma",
        "Stage IV Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-labeled GRPR Antagonist BAY86-7548",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Andrei Iagaru",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2017-04-10",
      "completion_date": "2021-12-19",
      "has_results": true,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03113617"
    },
    {
      "nct_id": "NCT01697930",
      "title": "A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Malignancy",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "[18F] 4-L-Fluoroglutamine (2S,4R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 67,
      "start_date": "2012-09",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697930"
    },
    {
      "nct_id": "NCT07249372",
      "title": "DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "DRP-104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2026-01-14",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07249372"
    },
    {
      "nct_id": "NCT03428217",
      "title": "CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 444,
      "start_date": "2018-04-24",
      "completion_date": "2021-07-16",
      "has_results": true,
      "last_update_posted_date": "2023-03-20",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03428217"
    },
    {
      "nct_id": "NCT02071862",
      "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Triple-Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Mesothelioma",
        "Fumarate Hydratase (FH)-Deficient Tumors",
        "Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)",
        "Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors",
        "Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations",
        "Tumors Harboring Amplifications in the cMyc Gene"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Pac-CB",
          "type": "DRUG"
        },
        {
          "name": "CBE",
          "type": "DRUG"
        },
        {
          "name": "CB-Erl",
          "type": "DRUG"
        },
        {
          "name": "CBD",
          "type": "DRUG"
        },
        {
          "name": "CB-Cabo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2014-02",
      "completion_date": "2019-03",
      "has_results": false,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Stanford, California • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071862"
    },
    {
      "nct_id": "NCT04305769",
      "title": "Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridioides Difficile Infection",
        "Clostridium Difficile Infection",
        "Clostridium Difficile Diarrhea",
        "Clostridia Difficile Colitis"
      ],
      "interventions": [
        {
          "name": "Alanyl-glutamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "105 Years",
        "sex": "ALL",
        "summary": "18 Years to 105 Years"
      },
      "enrollment_count": 260,
      "start_date": "2021-06-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 2,
      "location_summary": "Charlottesville, Virginia • Roanoke, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305769"
    },
    {
      "nct_id": "NCT00216970",
      "title": "Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Alteration in nutritional support",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "1997-08",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2009-08-13",
      "last_synced_at": "2026-09-24T06:32:47.257Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00216970"
    }
  ]
}